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Abstract: People seeking treatment for substance use disorders (SUD) ultimately aspire to improve
their quality of life (QOL) through reducing or ceasing their substance use, however the association
between these treatment outcomes has received scant research attention. In a prospective, multi-site
treatment outcome study (‘Patient Pathways’), we recruited 796 clients within one month of intake
from 21 publicly funded addiction treatment services in two Australian states, 555 (70%) of whom were
followed-up 12 months later. We measured QOL at baseline and follow-up using the WHOQOL-BREF
(physical, psychological, social and environmental domains) and determined rates of “SUD treatment
success” (past-month abstinence or a statistically reliable reduction in substance use) at follow-up.
Mixed effects linear regression analyses indicated that people who achieved SUD treatment success
also achieved significantly greater improvements in QOL, relative to treatment non-responders
(all four domains p < 0.001). Paired t-tests indicated that non-responders significantly improved their
social (p = 0.007) and environmental (p = 0.033) QOL; however, their psychological (p = 0.088) and
physical (p = 0.841) QOL did not significantly improve. The findings indicate that following treatment,
QOL improved in at least some domains, but that reduced substance use was associated with both
stronger and broader improvements in QOL. Addressing physical and psychological co-morbidities
during treatment may facilitate reductions in substance use.
Keywords: quality of life; substance use treatment; substance use disorder; reduced substance use;
abstinence; treatment outcome; addiction; alcohol and drugs
1. Introduction
Previous outcome studies have consistently reported high rates of cessation or substantial
reduction in substance use following treatment [1–9]. However, substance use disorders (SUD) affect
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multiple other areas of health and psychosocial functioning, and improvement in these domains is
also a common goal of treatment. As noted by Ray, Lim, and Shoptaw [10], “A vague but universal
objective among individuals entering addiction treatment is to ‘get their life back’”. Indeed, a panel
of treatment and research experts convened by the US National Institute on Drug Abuse (NIDA)
in 2009 recommended that SUD treatment outcome research seek to measure a number of other
domains, specifically, craving, psychosocial functioning, self-efficacy, quality of life (QOL), and social
support [11]. However, Tiffany et al. [11] observed that, at that time, addiction research lagged behind
other biomedical fields in terms of evaluating QOL outcomes.
Nevertheless, several major treatment outcome studies have included measures of health-related
QOL, such as the 12-item [12] or 36-item versions of the Short Form Health Survey [13] (SF-12 and
SF-36, respectively). The Australian Treatment Outcome Study (ATOS) of people entering treatment
for heroin dependence found improvements in SF-12 physical health, which reached levels similar to
general population norms one year following treatment entry, whilst psychological health remained
below population norms despite improving [14–16]. Similarly, in the UK Drug Treatment Outcomes
Research Study (DTORS), changes in SF-12 scores indicated improvements in psychological health
3–5 months after treatment, though again, with mean scores remaining below general population
norms, whilst mean physical health scores, already similar to general population norms at baseline,
remained unchanged [8]. Other studies have observed improvements in physical and psychological
well-being after treatment using measures other than QOL scales [1,3,5,7].
Another widely-used QOL measure is the brief version of the World Health Organization Quality
of Life scale (WHOQOL-BREF) [17] which, in addition to physical and mental QOL, also assesses
social, and environmental (e.g., financial resources; opportunities for leisure and skill-acquisition) QOL.
Significant improvements in all four QOL domains have been reported following commencement
of treatment in several studies of OST for opioid use disorder [18–21] and also at 6- and 12-month
follow-ups in a large alcohol use disorder treatment study [22]. In another study focused on women
receiving treatment for SUD, all WHOQOL-BREF domains except social QOL significantly improved
6 months after treatment intake [23].
Poor QOL as a result of a substance-using lifestyle is often the impetus for help-seeking.
Numerous studies report that negative social consequences of substance use are often major reasons
for treatment-seeking [24–27], with one study identifying that they were a stronger predictor of
entering treatment than dependence symptoms [27]. Medical and psychological problems have also
been reported as either predictors, or common precipitators, of SUD treatment-seeking in several
studies [24,25,27]. The corollary is that improvements in social, psychological, and physical QOL are
often likely to be an important outcome for clients, and one which may help them maintain reductions
in substance use over the long term. However, it remains unclear whether these two types of outcomes
(reduced substance use and improved QOL) are related to or dependent on each other. Few studies
have examined these associations using measures specifically designed to assess QOL. In DTORS,
those who reported past 3-month abstinence from illicit drugs (other than cannabis) at a 33-month
follow-up had nearly five times the odds of an improvement in SF-36 psychological health score greater
than one standard deviation (SD) above the total sample’s average improvement [9]. In contrast,
Tracy et al. [23] found relatively little evidence that substance use at follow-up was associated with
QOL outcomes on the WHOQOL-BREF, with abstinence from alcohol at follow-up and environmental
QOL being the only significant association.
Kiluk et al. [28] recently challenged the value of using global measures of psychosocial
functioning in addiction treatment research and suggested measures of specific wellbeing/psychosocial
consequences that can be causally attributed to substance use are more clinically meaningful. However,
it may be difficult to distinguish between consequences that are clearly substance use-related, indirectly
related, or unrelated, especially over the long time-frames of many treatment outcome studies.
Indeed, the paucity of studies addressing this question precludes us from drawing any conclusion
on whether or not QOL is related to other clinically meaningful outcomes. Thus, to advance the
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literature around the validity of general QOL scales as outcome measures, we analysed data from
a large Australian treatment outcome study to examine whether reducing/ceasing substance use
was associated with improvements on the four QOL domains measured by the WHOQOL-BREF.
We hypothesised that participants who reduced/ceased use of their primary drug of concern (PDOC)
would show larger improvements in QOL than those who did not reliably reduce their PDOC use
(“treatment non-responders”). Nonetheless, we also explored whether there were still detectable
improvements in QOL among treatment non-responders, despite their continued substance use.
2. Methods
‘Patient Pathways’ was a prospective treatment outcome study. The participants, measures,
and procedures have been described extensively elsewhere [29–31] and, for the sake of brevity, only
aspects pertinent for understanding the current analyses are summarised below. Ethics approval was
provided by the Eastern Health Human Research Ethics Committee (E17/1112), Monash University
Human Research Ethics Committee (201200020) and Curtin University (HR11/2012).
Participants and setting: 796 participants aged ≥18 years, who had commenced treatment within
the past month, were recruited from 21 different specialist alcohol/drug services across 37 different
sites in Victoria and Western Australia (WA) including acute withdrawal, residential rehabilitation and
outpatient settings. Baseline interviews were conducted between January 2012 and January 2013 and
555 (70%) participants completed a 1-year follow-up. Due to missing data regarding either substance
use or QOL, the present analyses included 536 participants (for physical and psychological QOL) or
535 participants (for social and environmental QOL).
Relevant measures: At both baseline and follow-up, researchers administered a battery of
questionnaires which included measures of demographic characteristics, substance use, and QOL.
Participants were asked to identify their PDOC and frequency of use of all licit and illicit substances
in the past 30 days was measured using the ASSIST [32]. QOL was measured using the 24 items
measuring the four domains of the WHOQOL-BREF (physical, psychological, social and environmental).
The WHOQOL-BREF has been shown to have cross-cultural applicability and strong reliability and
validity in both general population and physical and mental health treatment samples [17], as well as
an alcohol use disorder treatment sample [22]. Australian general population norms were published
for the WHOQOL-BREF in 2006 [33].
Analyses: SUD treatment success was defined as achieving either of two outcomes: abstinence from
the PDOC (the predominant treatment goal for 74.0% of participants) in the 30 days prior to follow-up,
or a statistically-reliable reduction in days of PDOC use in the past month at follow-up, relative to
baseline. Reliable change criteria (RCC) were calculated using the Jacobson and Truax [34] formula,
utilising reliability indices reported by Ryan et al. [35]. Further details of these calculations are
provided in Supplementary Materials. Differences in QOL outcomes at follow-up between participants
who achieved treatment success and non-responders were analysed using Stata version 14. Mixed
effects linear regression was undertaken separately for each WHOQOL-BREF domain, assessing the
time × treatment success interaction to test whether participants achieving SUD treatment success
showed a greater change in WHOQOL-BREF scores between baseline and follow-up, relative to
SUD treatment non-responders. Multivariate analysis adjusted for age, sex, PDOC, primary index
treatment (PIT) type at baseline (i.e., outpatient, withdrawal management, or residential rehabilitation),
whether or not the PIT was ended early, and time between baseline and follow-up. Separate paired
t-tests were used to test whether changes in WHOQOL-BREF scores were significant in treatment
responders and non-responders. One-sample t-tests were used to test whether QOL scores differed
significantly from general population means. Independent samples t-tests were used to compare SUD
treatment responders’ WHOQOL-BREF scores to those of SUD treatment non-responders at baseline
and at follow-up.
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3. Results
Table 1 describes baseline characteristics of the 536 participants included in these analyses. Mean
scores on all domains of the WHOQOL-BREF were between 1 to 2 SDs below the Australian general
population mean (physical: t (535) = −24.03; psychological: t (535) = −27.52; social: t (534) = 26.85;
environmental: t (534) = −19.44; all p < 0.001). Follow-ups occurred a mean of 381.1 days (SD = 71.9)
after the baseline interview, and at the time of the follow-up, 66.1% of participants had completed
their PIT, 5.6% were still engaged with it, and 28.2% had left or been expelled from their PIT prior
to completion. Half (51.9%) met the criterion for SUD treatment success (38.4% because they were
abstinent at follow-up, 13.4% because they reliably reduced number of days of use of the PDOC, despite
not being abstinent). Participants missing from analyses due to either loss to follow-up or missing QOL
or treatment outcome data (n = 260) were significantly younger (mean = 35.00 ± 10.79 versus mean =
38.16 ± 10.64, t (789) = −3.897, p < 0.001); and more likely to have amphetamines, and less likely to
have alcohol, as their PDOC (Pearson χ2 = 12.784, p = 0.012). Participants recruited from residential
rehabilitation (41.7%) and acute withdrawal (33.0%) were more likely to be missing from analyses than
those recruited from outpatient settings (22.0%, χ2 = 19.802, p < 0.001). There were no differences in
gender between those included in and those missing from analyses (χ2 = 1.553, p = 0.213) nor in any
domain of baseline WHOQOL-BREF scores (all p > 0.05).
Table 1. Baseline demographic and clinical characteristics of participants.
Variable Value
Age (years), mean (SD) 38.2 (10.6)
Sex
Male 324 (60.4%)
Female 210 (39.2%)
Missing 2 (0.4%)
Primary drug of concern (PDOC)
Alcohol 268 (50.0%)
Cannabis 84 (15.7%)
Opiates 81 (15.1%)
Amphetamines 90 (16.8%)
Other 13 (2.4%)
Primary index treatment (PIT)
Outpatient 167 (31.2%)
Acute withdrawal 235 (43.8%)
Residential rehabilitation 134 (25.0%)
Physical quality of life, mean (SD) WHOQOL-BREF numerical score 52.4 (20.3)
Australian population z-score 1 −1.16 (1.12)
Psychological quality of life,
mean (SD)
WHOQOL-BREF numerical score 45.3 (21.3)
Australian population z-score 1 −1.81 (1.52)
Social quality of life, mean (SD) WHOQOL-BREF numerical score 43.4 (24.2)
Australian population z-score 1 −1.55 (1.33)
Environmental quality of life,
mean (SD)
WHOQOL-BREF numerical score 59.1 (19.0)
Australian population z-score 1 −1.23 (1.46)
WHOQOL-BREF: World Health Organization Quality of Life Scale (Brief version). 1 WHOQOL-BREF scores
expressed as Australian general population standard deviations from the Australian population mean, according to
normative data published by Hawthorne et al. [33].
Table 2 shows WHOQOL-BREF scores for each QOL domain separately for treatment responders
and non-responders. Both groups had similar scores across all four domains at baseline. Among
treatment responders, improvements in QOL were significant for all four domains. The increases
in score were equivalent to improvements of 0.73, 1.07, 0.92, and 0.75 general population SDs for
the physical, psychological, social, and environmental domains, respectively. Thus, at follow-up,
their mean scores were all within one SD of population norms (physical: −0.46, SD = 1.19; psychological:
−0.77, SD = 1.50; social: −0.72, SD = 1.43; environmental: −0.49, SD = 1.26). Nevertheless, these scores
J. Clin. Med. 2019, 8, 1407 5 of 10
were still significantly lower than general population norms (physical: t (277) = −6.45; psychological:
t (277) = −8.57; social: t (277) = −8.35; environmental: t (277) = 6.51; all p < 0.001). Among treatment
responders, non-abstinent participants who reliably reduced their PDOC use showed similar QOL
improvements to those who achieved abstinence at follow-up (see Supplementary Materials, including
Figure S1).
For SUD treatment non-responders, there were no significant changes in physical or psychological
QOL scores between baseline and follow-up. While increases in social and environmental QOL
were statistically significant in SUD treatment non-responders, the magnitude of improvement was
equivalent to only 0.24 and 0.18 Australian general population SDs, respectively. Thus, at follow-up,
non-responders’ mean scores were still more than one SD below general population norms for all
domains (physical: −1.12, SD = 1.13, t (257) = −15.83; psychological: −1.60, SD = 1.54, t (257) = −16.63;
social: −1.21, SD = 1.35, t (257) = −14.38; environmental: −1.03, SD = 1.38, t (257) = −11.94; all p < 0.001).
As shown in Table 2, linear regression analyses found that the time x treatment success interactions
were significant for all QOL domains, confirming that improvements in QOL were significantly larger
in treatment responders than in non-responders.
Further exploratory repeated measures ANOVA analyses examined whether these interactions
were consistent across PDOC (i.e., alcohol versus illicit drug). There were no significant three-way
interactions between PDOC, time, and treatment success for environmental, social or physical QOL,
but there was a significant three-way interaction for psychological QOL (F (1,532) = 4.874, p = 0.028,
η2p = 0.009). This interaction is explored further in Supplementary Materials. Importantly, despite this
three-way interaction, the two-way interaction between time and treatment success was significant
in both PDOC groups (see Supplementary Results, including Figure S2), suggesting that the main
finding (i.e., that improvement in psychological QOL was greater in treatment responders than in
non-responders) was consistent, despite this association being stronger in those with alcohol as their
PDOC. In addition, there were no 2-way interactions between PDOC and time, suggesting no general
effect of PDOC on changes in QOL over time.
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Table 2. Changes in WHOQOL-BREF scores between baseline and follow-up, compared between those who achieved treatment success vs. those who did not,
with results of linear regression models testing the time x treatment success interactions.
QOL Domain 3 Treatment
Success
Baseline
Mean (SD)
Follow-up
Mean (SD)
P-Value for Within-Category
Change from Baseline to
Follow-up 1
Unadjusted Adjusted 2
Estimated
Difference 95% CI p-Value
Estimated
Difference 95% CI p-Value
Physical No 53.0 (18.5) 53.3 (20.5) 0.841 12.99 9.43–16.56 <0.001 13.22 9.66–16.78 <0.001Yes 51.9 (21.8) 65.1 (21.6) <0.001
between-groups
p-value 0.504 <0.001
Psychological No 45.8 (19.9) 48.2 (21.6) 0.088 12.65 8.73–16.58 <0.001 12.98 9.06–16.89 <0.001Yes 44.8 (22.5) 59.8 (21.0) <0.001
between-groups
p-value 0.588 <0.001
Social
No 45.2 (23.4) 49.6 (24.5) 0.007
12.37 7.63–17.11 <0.001 12.91 8.20–17.62 <0.001Yes 41.7 (24.8) 58.5 (26.0) <0.001
between-groups
p-value 0.101 <0.001
Environmental
No 59.3 (18.7) 61.7 (18.0) 0.033
7.24 3.84–10.64 <0.001 7.38 3.96–10.80 <0.001Yes 59.0 (19.3) 68.7 (16.4) <0.001
between-groups
p-value 0.816 <0.001
QOL: quality of life. Estimated difference refers to estimated difference in effect between the abstinent group, compared to non-abstinent, group over time. 1 p value for change from
baseline to follow-up in paired-samples t-tests conducted separately within each treatment success category. 2 Adjusted for age, sex, time between baseline and follow-up, primary index
treatment (PIT) type, whether or not PIT was ceased early (i.e., neither completed as planned nor still continuing at follow-up), and primary drug of concern. 3 For comparison, Australian
general population norms published by Hawthorne et al. are 73.5 (18.1), 70.6 (14.0), 71.5 (18.2), and 75.1 (13.0) for physical, psychological, social, and environmental domains, respectively.
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4. Discussion
Consistent with previous findings of improved QOL following engagement with treatment
for SUD [8,16,18–23], we observed improvements in all four domains of the WHOQOL-BREF at
the one-year follow-up. However, for physical and psychological QOL, these improvements were
only significant in participants who substantially reduced their frequency of use of, or ceased using,
their PDOC. Although SUD treatment non-responders showed significant increases in social and
environmental QOL, these were significantly smaller than the increases shown by SUD treatment
responders. In contrast to Kiluk et al.’s [28] proposition that outcomes indexed by general measures of
well-being were relatively unrelated to substance use outcomes, these findings suggest that outcomes
measured by the WHOQOL-BREF were robustly related to substance use outcomes, suggesting that
this instrument offers important and relevant information about treatment outcomes.
While some previous reports found associations between improved psychological well-being
and substance use outcomes [9,36–38], several studies have reported that these associations are weak,
and are also generally weak or absent for indicators of physical and social QOL [23,36–39]. However,
of the reports suggesting weak or absent associations between changes in well-being and substance
use following treatment, only one [23] used a measure designed specifically to measure QOL, and this
was conducted with a modest-sized, female-only sample. Moreover, these previous studies were based
in the US, and it is unclear whether differences between the US and Australian treatment systems,
or more broadly (e.g., differences in culture or patterns of substance use) may explain why we found
much stronger evidence for these associations than these previous studies.
Given that this was a naturalistic non-randomised cohort study with only one follow-up in which
QOL and substance use outcomes were assessed at the same time, we cannot draw causal conclusions
regarding our findings. Our ability to interpret these findings is also limited by the fact that 30% of the
baseline sample was lost to follow-up. Thus, our analyses might overestimate actual improvements in
QOL, and this may bias our findings regarding the degree of association between these improvements
and substance use outcomes. Moreover, participants missing from these analyses were younger than
those included in these analyses, and differed from those included in terms of PDOC and PIT, and this
may also bias our analyses and/or limit generalisability. Moreover, improvements in QOL may partly
reflect regression to the mean, particularly given that people are likely to be at a particularly “low point”
in their lives when entering SUD treatment. Thus, in the absence of a non-treatment control group,
the improvements in social and environmental QOL in treatment non-responders cannot reliably
be attributed to SUD treatment. While it could be argued that regression to the mean in treatment
responders should be reflected in all four QOL domains, not just social and environmental, their lack of
a significant improvement in physical and psychological QOL may be due to the fact that these domains
are more intrinsically related to substance use. One final limitation is that psychiatric diagnosis was
not assessed, and therefore its impact on changes in QOL could not be examined.
Despite these caveats, our findings are suggestive of two similarly plausible explanations (which are
not mutually exclusive, and indeed may operate together in a mutually reinforcing manner). One is that
substance use (directly and/or indirectly) negatively impacts, and/or prevents improvements in, QOL.
Thus, those who reduce their substance use are “freed” from these negative impacts and are more likely
to experience improvements in QOL. This would suggest that treatments effective at reducing substance
use (i.e., psychotherapeutic interventions, peer support/mutual aid, pharmacotherapy, and residential
rehabilitation) are also inherently beneficial to QOL. This emphasises the importance of increasing
the availability of, and facilitating clients’ access to, these treatments, as well as finding ways to
maximise rates of treatment completion [31]. Nevertheless, the significant (albeit small) improvements
in social and environmental QOL seen among treatment non-responders suggest that treatment may
be beneficial even to those who achieve little or no change in their substance use. The unexpected
improvements in social QOL could be attributed to the fostering of new social relationships, including
connecting with others in SUD treatment or mutual aid/peer support (attended by 48.6% [31]), and/or by
strengthening social support or pre-existing relationships by virtue of the participant entering treatment
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to address their SUD. Moreover, by being in treatment participants could have been referred to social
and welfare services (e.g., housing, employment agencies etc.), leading to improved financial security,
safety, comfort and convenience of their living environment, and improved access to resources and
meaningful activities, thereby accounting for an improved environmental QOL.
The alternative explanation is that experiencing improvements in QOL facilitates, or motivates,
reductions in substance use. For example, in line with the self-medication hypothesis [40], participants
may have continued using substances as a coping mechanism for managing psychological distress,
pain, or severe/complex psychosocial issues, and may become much more likely to reduce their
substance use only after finding alternate solutions that improve their QOL. This would suggest
that, for clients with poor physical and/or psychological wellbeing (a substantial proportion of the
treatment-seeking population) and with poor QOL more generally, finding solutions to these problems
would often be necessary to achieve reductions in substance use. Indeed, Hunt and Azrin’s [41] small
trial of the “community reinforcement” approach, an intensive approach aimed at improving social and
environmental QOL, contingent on abstaining from alcohol, found that it led to high rates of abstinence
among alcohol-dependent men. This also emphasises the importance of integrated care and referral
between addiction treatment and other mental health, medical, social (e.g., housing and employment)
services, and peer support, to achieve not only improvements in these domains, but potentially in
substance use as well. Nonetheless, the influence of other variables (e.g., demographic and clinical
characteristics) on changes in QOL, particularly whether other factors moderate or mediate associations
between treatment success and improvement in quality of life, warrants examination in future research.
Supplementary Materials: Supplementary methods and results are available online at http://www.mdpi.com/
2077-0383/8/9/1407/s1, including Figure S1: Scores on each WHOQOL-BREF domain at baseline and follow-up
among those who were abstinent at follow-up; those who reliably reduced use of their primary drug of concern
(PDOC), but were not abstinent at follow-up; and those who did not reliably reduce the frequency of use of their
PDOC, Figure S2: Changes in psychological QOL between baseline and follow-up among treatment responders
(solid lines) and non-responders (dashed lines), shown separately for those with alcohol as PDOC (top panel), and
those with any other drug as their PDOC (bottom panel).
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